QCI Asset Management Inc. NY Acquires 8,099 Shares of Bristol-Myers Squibb Co (BMY)

QCI Asset Management Inc. NY grew its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 239,865 shares of the biopharmaceutical company’s stock after acquiring an additional 8,099 shares during the period. Bristol-Myers Squibb comprises 1.7% of QCI Asset Management Inc. NY’s holdings, making the stock its 24th biggest position. QCI Asset Management Inc. NY’s holdings in Bristol-Myers Squibb were worth $15,289,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Blue Chip Partners Inc. boosted its holdings in shares of Bristol-Myers Squibb by 0.7% in the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the last quarter. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 15 shares during the period. Chilton Investment Co. LLC lifted its stake in shares of Bristol-Myers Squibb by 0.5% in the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 26 shares during the period. Keel Point LLC lifted its stake in shares of Bristol-Myers Squibb by 0.6% in the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after purchasing an additional 39 shares during the period. Finally, Hudock Capital Group LLC lifted its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after purchasing an additional 49 shares during the period. 69.67% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Co (BMY) opened at $62.81 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47. The firm has a market cap of $102,801.13, a price-to-earnings ratio of 21.22, a price-to-earnings-growth ratio of 2.30 and a beta of 1.18. Bristol-Myers Squibb Co has a 12-month low of $46.01 and a 12-month high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The business’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be given a dividend of $0.40 per share. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.99%.

Several research firms recently issued reports on BMY. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 target price for the company. in a research note on Thursday, December 28th. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Monday, December 11th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Tuesday, December 5th. Finally, SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Monday, October 30th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $65.05.

In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now directly owns 9,251 shares in the company, valued at $585,033.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The disclosure for this sale can be found here. Corporate insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thestockobserver.com/2018/01/14/qci-asset-management-inc-ny-acquires-8099-shares-of-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply